Summary & Overview
Knee Procedures with Principal Diagnosis of Infection with MCC: Inpatient Reimbursement Overview
DRG 485 encompasses knee procedures where the principal diagnosis is infection accompanied by a Major Complication or Comorbidity; it covers operative and perioperative care related to infected native knees or prosthetic joint infections. This Diagnosis-Related Group is important for inpatient reimbursement because infection and Major Complication or Comorbidity status increase expected resource consumption and affect Medicare payment classification.
DRG 485 Overview
DRG 485 covers knee procedures performed when the principal diagnosis is an infection with Major Complication or Comorbidity. This category captures cases that typically require operative intervention for infected knee joints or prostheses and often involve intensive medical management. It matters for Medicare payment because the presence of infection and a Major Complication or Comorbidity significantly increases resource use and drives higher Diagnosis-Related Group reimbursement. Accurate clinical documentation of the infection and associated Major Complication or Comorbidity is essential for appropriate assignment to this Diagnosis-Related Group.
Clinical Trials
- Acute surgical management trials: randomized or prospective cohort studies comparing different intraoperative strategies for infected knee procedures, such as debridement and implant retention versus staged exchange arthroplasty, often stratified by presence of multidrug-resistant organisms or biofilm-forming pathogens. These studies enroll hospitalized adults with a principal diagnosis of septic knee joint or periprosthetic joint infection and aim to define which operative approach leads to higher short-term infection control, lower 30–90 day readmission, and reduced need for additional surgeries. Results are directly relevant to surgeons, hospital administrators, and payers because they inform resource-intensive decisions that drive length of stay, operative costs, and early reimbursement outcomes under this DRG.
- Antimicrobial strategy and optimization studies: comparative effectiveness and pharmacokinetic/pharmacodynamic trials evaluating intravenous antibiotic regimens, duration of therapy, and local antimicrobial delivery (for example, antibiotic-loaded cement spacers) in patients undergoing treatment for knee infections. These trials focus on inpatient and early post-acute populations with confirmed septic arthritis or prosthetic joint infection, assessing clinical cure rates, adverse events, and impacts on hospital resource use such as days of IV therapy versus transition to oral agents. Findings matter to clinicians and payers because antibiotic choice and duration influence inpatient length of stay, complication rates, antimicrobial stewardship metrics, and downstream costs related to readmissions and long-term disability.
- Post-discharge functional outcomes and care-transition studies: prospective observational cohorts or pragmatic trials examining rehabilitation protocols, outpatient wound care models, and coordinated home health services for patients discharged after infected knee procedures, with endpoints including functional mobility, prosthesis retention, and 90–180 day healthcare utilization. These studies enroll survivors of the acute hospitalization for knee infection—often older adults with comorbidities—and evaluate how different discharge pathways affect recovery, readmission risk, and durable outcomes. Payers and healthcare systems use this evidence to design case management, bundle payments, and post-acute care networks that can reduce costly readmissions and improve long-term functional outcomes for this high-risk DRG population.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.